Document Detail

CCL11 (eotaxin-1): a new diagnostic serum marker for prostate cancer.
MedLine Citation:
PMID:  23059958     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: The recent recommendation of the U.S. Preventive Services Task Force against PSA-based screening for prostate cancer was based, in part, on the lack of demonstrated diagnostic utility of serum PSA values in the low, but detectable range to successfully predict prostate cancer. Though controversial, this recommendation reinforced the critical need to develop, validate, and determine the utility of other serum and/or urine transcript and protein markers as diagnostic markers for PCa. The studies described here were intended to determine whether inflammatory cytokines might augment serum PSA as a diagnostic marker for prostate cancer.
METHODS: Multiplex ELISA assays were performed to quantify CCL1, CCL2, CCL5, CCL8, CCL11, CCL17, CXCL1, CXCL5, CXCL8, CXCL10, CXCL12, and IL-6 protein levels in the serum of 272 men demonstrating serum PSA values of <10 ng/ml and undergoing a 12 core diagnostic needle biopsy for detection of prostate cancer. Logistic regression was used to identify the associations between specific chemokines and prostate cancer status adjusted for prostate volume, and baseline PSA.
RESULTS: Serum levels for CCL1 (I-309) were significantly elevated among all men with enlarged prostates (P < 0.04). Serum levels for CCL11 (Eotaxin-1) were significantly elevated among men with prostate cancer regardless of prostate size (P < 0.01). The remaining 10 cytokines examined in this study did not exhibit significant correlations with either prostate volume or cancer status.
CONCLUSIONS: Serum CCL11 values may provide a useful diagnostic tool to help distinguish between prostatic enlargement and prostate cancer among men demonstrating low, but detectable, serum PSA values.
Manisha Agarwal; Chang He; Javed Siddiqui; John T Wei; Jill A Macoska
Related Documents :
11507068 - An adenovirus expressing mutant p27 showed more potent antitumor effects than adenoviru...
18544338 - Autonomous hedgehog signalling is undetectable in pc-3 prostate cancer cells.
16836568 - Enhancing effect of platelet-derived microvesicles on the invasive potential of breast ...
21081148 - Antioxidant and anti-neoplastic activities of picrorhiza kurroa extracts.
6472518 - The epidemiological risk factors of the larynx cancer among the native and migrant male...
21667238 - Responsiveness of adjacent ductal carcinoma in situ and changes in her2 status after ne...
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural     Date:  2012-10-11
Journal Detail:
Title:  The Prostate     Volume:  73     ISSN:  1097-0045     ISO Abbreviation:  Prostate     Publication Date:  2013 May 
Date Detail:
Created Date:  2013-04-04     Completed Date:  2013-05-28     Revised Date:  2014-06-24    
Medline Journal Info:
Nlm Unique ID:  8101368     Medline TA:  Prostate     Country:  United States    
Other Details:
Languages:  eng     Pagination:  573-81     Citation Subset:  IM    
Copyright Information:
Copyright © 2012 Wiley Periodicals, Inc.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Biological Markers / blood
Chemokine CCL1 / blood
Chemokine CCL11 / blood*
Diagnosis, Differential
Kallikreins / blood
Middle Aged
Neoplasm Grading
Predictive Value of Tests
Prostate / pathology
Prostate-Specific Antigen / blood
Prostatic Neoplasms / blood*,  diagnosis*,  epidemiology
Risk Factors
Tumor Markers, Biological / blood*
Grant Support
U01 CA086402/CA/NCI NIH HHS; U01 CA086402/CA/NCI NIH HHS
Reg. No./Substance:
0/Biological Markers; 0/CCL1 protein, human; 0/CCL11 protein, human; 0/Chemokine CCL1; 0/Chemokine CCL11; 0/Tumor Markers, Biological; EC 3.4.21.-/Kallikreins; EC 3.4.21.-/kallikrein-related peptidase 3, human; EC Antigen

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Ternary Donor-Insulator-Acceptor Systems for Polymer Solar Cells.
Next Document:  Predictors of bloodstream infection associated with permanently implantable venous port in solid can...